Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human GPBAR1 Antibodies:
anti-Rat (Rattus) GPBAR1 Antibodies:
anti-Mouse (Murine) GPBAR1 Antibodies:
Go to our pre-filtered search.
Human Monoclonal GPBAR1 Primary Antibody for CyTOF, FACS - ABIN4899058
Yoneno, Hisamatsu, Shimamura, Kamada, Ichikawa, Kitazume, Mori, Uo, Namikawa, Matsuoka, Sato, Koganei, Sugita, Kanai, Hibi: TGR5 signalling inhibits the production of pro-inflammatory cytokines by in vitro differentiated inflammatory and intestinal macrophages in Crohn's disease. in Immunology 2013
Human Polyclonal GPBAR1 Primary Antibody for IHC (p) - ABIN4359103
Alemi, Poole, Chiu, Schoonjans, Cattaruzza, Grider, Bunnett, Corvera: The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice. in Gastroenterology 2012
RYGB increased circulating bile acids, ileal Takeda G protein-coupled receptor 5 (show XCR1 Antibodies) (TGR5) and mTORC1 signaling activity, as well as GLP-1 (show GCG Antibodies) production in both mice and human subjects. Inhibition of ileal mTORC1 signaling by rapamycin significantly attenuated the stimulation of bile acid secretion, TGR5 expression and GLP-1 (show GCG Antibodies) synthesis induced by RYGB in lean and diet-induced obese mice.
TGR5 is strongly expressed in collecting ducts, distal convoluted tubules and thin loop of Henle. TGR5 protein and mRNA expression were notably decreased in clear cell renal cell carcinomas and may be helpful in differentiating these tumors from other renal cell carcinomas.
The findings suggest that activation of TGR5 promoted mitochondrial biogenesis in endothelial cells, which is mediated by the CREB (show CREB1 Antibodies)/PGC (show PGC Antibodies)-1a signaling pathway.
Higher-order oligomers, likely with a tetramer organization, are formed from dimers, the smallest unit suggested for TGR5 Y111A variants.
Data suggest that TGR5 and FXR (show NR1H4 Antibodies) in intestinal mucosa are important for glucose homeostasis, in particular in metabolic disorders such as type 2 diabetes and obesity. (TGR5 = membrane-type receptor for bile acids TGR5; FXR (show NR1H4 Antibodies) = farnesoid X receptor (show xpr1 Antibodies)) [REVIEW; Congress as Topic]
The authors conclude that taurodeoxycholic acid-induced DNA damage may depend on the activation of TGR5, CREB (show CREB1 Antibodies) and NOX5 (show NOX5 Antibodies)-S. It is possible that in Barrett's patients bile acids may activate NOX5 (show NOX5 Antibodies)-S and increase reactive oxygen species (ROS (show ROS1 Antibodies)) production via activation of TGR5 and CREB (show CREB1 Antibodies). NOX5 (show NOX5 Antibodies)-S-derived ROS (show ROS1 Antibodies) may cause DNA damage, thereby contributing to the progression from Barrett's esophagus to esophageal adenocarcinoma.
GPBAR1 is expressed in advanced gastric cancers and its expression correlates with markers of epithelial-mesenchymal transition
TGR5 activation induces mitochondrial biogenesis and prevents renal oxidative stress and lipid accumulation, establishing a role for TGR5 in inhibiting Kidney Disease in Obesity and Diabetes Mellitus.
TGR5 exhibits significantly higher expression in NSCLC tumor samples and facilitates the growth and metastasis of NSCLC by activating the JAK2 (show JAK2 Antibodies)/STAT3 (show STAT3 Antibodies) signaling pathway.
TGR5 may have a role in the progression from Barrett's Esophagus to high-grade dysplasia and esophageal adenocarcinoma
TGR5 agonism induces NO production via Akt (show AKT1 Antibodies) activation and intracellular Ca(2 (show CA2 Antibodies)+) increase in vascular endothelial cells, and this function inhibits monocyte adhesion in response to inflammatory stimuli.
TGR5 has been linked to signaling pathways involved in metabolism, cell survival, proliferation and apoptosis, which suggest a possible role of TGR5 in cancer development.
G-protein coupled bile acid receptor 1 (TGR5) is required for cold-induced beiging of subcutaneous white adipose tissue (scWAT).
Work is the first to provide evidence for a TGR5-inhibited inflammatory response in ischemia/reperfusion injury through suppression of the TLR4 (show TLR4 Antibodies)-NF-kappaB (show NFKB1 Antibodies) pathway.
findings show GPBAR1 is essential for maintaining intestinal immune homeostasis and that its activation in the setting of inflammation reverses the immune dysfunction that occurs in rodent models of colitis
Data suggest that FXR (show NR1H4 Antibodies) and TGR5 expression is down-regulated in aging kidney; caloric restriction prevents these age-related changes. Additionally, in long-lived Ames dwarf (show PROP1 Antibodies) mice, renal FXR (show NR1H4 Antibodies) and TGR5 expression is up-regulated. Treatment of aged mice with dual FXR (show NR1H4 Antibodies)/TGR5 agonist reverses age-related changes in kidney structure/function. (FXR (show NR1H4 Antibodies) = farnesoid X activated receptor (show NR1H4 Antibodies); TGR5 = G protein-coupled bile acid receptor 1)
GPBAR1/TGR5 receptor agonist, tauroursodeoxycholic acid, has anti-inflammatory effects in microglial cells.
Vertical sleeve gastrectomy achieves its postoperative therapeutic effects through enhanced TGR5 signaling.
These results suggest that TGR5 contributes to the glucoregulatory benefits of vertical sleeve gastrectomy surgery by promoting metabolically favourable shifts in the circulating bile acid pool.
findings uncovered a novel mechanism in which INT-767 activation of FXR (show NR1H4 Antibodies) induces Tgr5 gene expression and increases Ca(2 (show CA2 Antibodies)+) levels and cAMP activity to stimulate GLP-1 (show GCG Antibodies) secretion and improve hepatic glucose and lipid metabolism in high-fat diet-induced obese mice.
The results suggest that TGR5 activation mediates cross-talk between alpha- and beta-cells by switching from glucagon (show GCG Antibodies) to GLP-1 (show GCG Antibodies) to restore beta- cell mass and function under hyperglycemic conditions.
TGR5 is an important mediator of bile acid-induced cholangiocyte proliferation in vivo and in vitro. Furthermore, TGR5 protects cholangiocytes from death receptor-mediated apoptosis.
This gene encodes a member of the G protein-coupled receptor (GPCR) superfamily. This enzyme functions as a cell surface receptor for bile acids. Treatment of cells expressing this GPCR with bile acids induces the production of intracellular cAMP, activation of a MAP kinase signaling pathway, and internalization of the receptor. The receptor is implicated in the suppression of macrophage functions and regulation of energy homeostasis by bile acids. Alternative splicing results in multiple transcript variants encoding the same protein.
G-protein coupled bile acid receptor 1
, G-protein coupled bile acid receptor BG37
, G-protein coupled receptor GPCR19
, membrane bile acid receptor
, membrane-type receptor for bile acids
, G protein-coupled receptor TGR5
, G protein-coupled receptor
, G protein-coupled bile acid receptor 1